AstraZeneca filed a lawsuit to prevent Apotex from selling a generic version of Pulmicort, a drug with nearly $1 billion in annual sales.
AstraZeneca's blockbuster drug Crestor was shown to reduce the risk of blood clots in veins. This gives the company a new potential application for the drug.
Previously, there was no mechanism for generic biologic drugs to be approved - which meant companies like Amgen don't face generic competition. But Obama's budget proposes to change that.
AstraZeneca announces its $15.6B acquisition of MedImmune. Investors send the company's stock down because the high price tag is seen as excessive.
AstraZeneca suffers another steep setback when a European court removes patent protection from AstraZeneca's top seller in Europe. Investors punish the company's stock.